Literature DB >> 24633668

Identification of subsets of patients with favorable prognosis after recurrence in completely resected non-small cell lung cancer.

Makoto Sonobe1, Tetsu Yamada, Masaaki Sato, Toshi Menju, Akihiro Aoyama, Toshihiko Sato, Fengshi Chen, Mitsugu Omasa, Toru Bando, Hiroshi Date.   

Abstract

BACKGROUND: This retrospective study aimed to determine prognostic factors associated with postrecurrence survival of completely resected non-small cell cancer patients with postoperative recurrence.
METHODS: Characteristics, treatment modality, and postrecurrence survival of 234 patients (157 males and 77 females, mean age at recurrence: 68.7 years, 152 adenocarcinomas and 82 non-adenocarcinomas), who underwent complete resection for non-small cell lung cancer between 2003 and 2009 at our hospital and experienced recurrence, were analyzed for prognostic factors. Cox proportional hazard model was applied for multivariate analysis.
RESULTS: Among 234 patients, the median survival time after the diagnosis of recurrence was 21 months, and the 5-year postrecurrence survival rate was 19.9 %. Eastern Cooperative Oncology Group Performance Status (ECOG PS) (hazard ratio [HR]: ECOG PS-0/PS-1/PS-2 = 1/3.313/7.622), time to recurrence after surgery (HR: >2 years/1-2 years/<1 year = 1/1.881/2.185), and number of initial recurrent organs (HR: 1 organ/2 organs/3 or more organs = 1/1.896/2.818) were independent prognostic factors. Patients who received resection or stereotactic irradiation for limited number of brain metastases or solitary extracranial metastasis, and those who received mediastinal radiation or chemoradiation for recurrence at regional lymph nodes and/or resected stump had better survival (median survival time after recurrence: 34, 64, and 25 months, respectively).
CONCLUSIONS: Poor ECOG PS, shorter time from initial surgery to recurrence, and increasing number of initial recurrent regions are associated with poor prognosis after recurrence. When the number of recurrent lesions is limited, intensive local treatment with curative intent should be applied for achieving long-term postrecurrence survival.

Entities:  

Mesh:

Year:  2014        PMID: 24633668     DOI: 10.1245/s10434-014-3630-9

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  18 in total

1.  Salvage Photon or Proton Radiotherapy for Oligo-recurrence in Regional Lymph Nodes After Surgery for Non-small Cell Lung Cancer.

Authors:  Masatoshi Nakamura; Kayoko Ohnishi; Hitoshi Ishikawa; Kensuke Nakazawa; Toshihiro Shiozawa; Toshiyuki Okumura; Ikuo Sekine; Yukio Sato; Nobuyuki Hizawa; Hideyuki Sakurai
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

2.  Prognostic Factors for Post Recurrence Survival in Resected Pathological Stage I Non-small Cell Lung Cancer.

Authors:  Yasuaki Kubouchi; Yoshiteru Kidokoro; Takashi Ohno; Yohei Yurugi; Makoto Wakahara; Tomohiro Haruki; Hiroshige Nakamura
Journal:  Yonago Acta Med       Date:  2018-02-05       Impact factor: 1.641

3.  Post-recurrence survival of elderly patients 75 years of age or older with surgically resected non-small cell lung cancer.

Authors:  Tomoyoshi Takenaka; Eiko Inamasu; Tsukihisa Yoshida; Gouji Toyokawa; Kaname Nosaki; Fumihiko Hirai; Masafumi Yamaguchi; Takashi Seto; Mitsuhiro Takenoyama; Yukito Ichinose
Journal:  Surg Today       Date:  2015-06-13       Impact factor: 2.549

4.  Adjuvant vinorelbine and cisplatin after complete resection of stage II and III non-small cell lung cancer: long-term follow-up of our study of Japanese patients.

Authors:  Makoto Sonobe; Masatsugu Hamaji; Hideki Motoyama; Toshi Menju; Akihiro Aoyama; Toyofumi F Chen-Yoshikawa; Toshihiko Sato; Hiroshi Date
Journal:  Surg Today       Date:  2018-03-03       Impact factor: 2.549

5.  Gefitinib treatment in patients with postoperative recurrent non-small-cell lung cancer harboring epidermal growth factor receptor gene mutations.

Authors:  Yuhei Yokoyama; Makoto Sonobe; Tetsu Yamada; Masaaki Sato; Toshi Menju; Akihiro Aoyama; Toshihiko Sato; Fengshi Chen; Mitsugu Omasa; Hiroshi Date
Journal:  Int J Clin Oncol       Date:  2015-05-08       Impact factor: 3.402

6.  FDG uptake at the bronchial stump after curative lobectomy for non-small cell lung cancer.

Authors:  Caroline Keyzer; Florence Corbusier; Eirini Kyratzi; Youri Sokolow; Pierre Alain Gevenois; Serge Goldman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-10-28       Impact factor: 9.236

7.  Current outcomes of postrecurrence survival in patients after resection of non-small cell lung cancer.

Authors:  Tetsuya Mizuno; Takaaki Arimura; Hiroaki Kuroda; Noriaki Sakakura; Yasushi Yatabe; Yukinori Sakao
Journal:  J Thorac Dis       Date:  2018-03       Impact factor: 2.895

8.  CT-guided iodine-125 brachytherapy as salvage therapy for recurrent mediastinal lymph node metastasis.

Authors:  Hong Dong; Lin Li; Dianjin Xing; Yuliang Li; Wujie Wang
Journal:  Thorac Cancer       Date:  2021-03-14       Impact factor: 3.500

9.  Prognostic factors in operated T3 non-small cell lung cancer: A retrospective, single-center study of 129 patients.

Authors:  Ahmet Uluşan; Maruf Şanlı; Ahmet Feridun Işık; Miray Ersöz; Bülent Tunçözgür; Kemal Bakır; Seval Kul; Levent Elbeyli
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2018-01-09       Impact factor: 0.332

10.  Identification of the Best Prognostic Marker Among Immunonutritional Parameters Using Serum C-Reactive Protein and Albumin in Non-Small Cell Lung Cancer.

Authors:  Taichi Matsubara; Shinkichi Takamori; Naoki Haratake; Takatoshi Fujishita; Ryo Toyozawa; Kensaku Ito; Mototsugu Shimokawa; Masafumi Yamaguchi; Takashi Seto; Tatsuro Okamoto
Journal:  Ann Surg Oncol       Date:  2020-10-21       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.